CytImmune Sciences
Founded Year
1996Stage
Unattributed - VIII | AliveTotal Raised
$11.38MLast Raised
$1M | 2 yrs agoMissing: CytImmune Sciences's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CytImmune Sciences's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing CytImmune Sciences
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
CytImmune Sciences is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
1,568 items
CytImmune Sciences Patents
CytImmune Sciences has filed 9 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/18/2010 | 7/22/2014 | Monoclonal antibodies, Molecular biology, Experimental cancer drugs, Peripherally selective drugs, Biotechnology | Grant |
Application Date | 2/18/2010 |
|---|---|
Grant Date | 7/22/2014 |
Title | |
Related Topics | Monoclonal antibodies, Molecular biology, Experimental cancer drugs, Peripherally selective drugs, Biotechnology |
Status | Grant |
Latest CytImmune Sciences News
Aug 24, 2022
Novel Nanotechnology Supercharges Immune System Molecules to Fight Cancer Researchers from Cytimmune Sciences presented new data at a cancer therapeutics conference in Boston, MA demonstrating the potential of their nanoparticle-based platform to supercharge synergistic immune system stimulators called cytokines. SUMMARY OF DATA PRESENTED Data focused on industry leading, first-in-class, multi-cytokine immunotherapies CYT-IFNg-TNFa (A dual cytokine immunotherapy nanomedicine) 100x increase in direct cancer cell killing potency vs native cytokines 30x increase in cytokine accumulation in tumor tissue Induction of a cancer specific immune response after treatment Other novel cytokine-based immunotherapies Introduction of nanomedicines including combinations of IL-12, IL-2, IL-15 & IL-1b 175x increase in potency of IL-12 presented on nanoparticles vs. native IL-12 CYT-6091 (high dose TNF alpha) Unpublished preclinical data showing CYT-6091 induces cytotoxic T-Cell tumor infiltration Phase 1 clinical safety data and preclinical mechanism of action data
CytImmune Sciences Frequently Asked Questions (FAQ)
When was CytImmune Sciences founded?
CytImmune Sciences was founded in 1996.
Where is CytImmune Sciences's headquarters?
CytImmune Sciences's headquarters is located at 15010 Broschart Road, Rockville.
What is CytImmune Sciences's latest funding round?
CytImmune Sciences's latest funding round is Unattributed - VIII.
How much did CytImmune Sciences raise?
CytImmune Sciences raised a total of $11.38M.
Who are the investors of CytImmune Sciences?
Investors of CytImmune Sciences include Montgomery County Department of Economic Development, Maryland Venture Fund and Maryland Department of Business & Economic Development.
Who are CytImmune Sciences's competitors?
Competitors of CytImmune Sciences include Humanetics, Soteria Biotherapeutics, PrevaCept Infection Control, Glaukos, GlobeImmune and 12 more.
Compare CytImmune Sciences to Competitors
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing drugs that enable targeted treatment of aggressive tumor diseases. The company's main objective is to extend the life expectancy of patients considerably and, at the same time, improve quality of life.
Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.
Prokaryon Technologies, Inc., is a animal health company that develops solutions for the prevention and control of economically devastating diseases in food animals. The focus of the company is the discovery, development, and commercialization of veterinary products. Prokaryon's lead product is a genomics-derived vaccine to prevent shipping fever in cattle.
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.